Atherosclerosis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Atherosclerosis – Pipeline Review, H1 2017’, provides an overview of the Atherosclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atherosclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Atherosclerosis

The report reviews pipeline therapeutics for Atherosclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Atherosclerosis therapeutics and enlists all their major and minor projects

The report assesses Atherosclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Atherosclerosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Atherosclerosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AFFiRiS AG

Allergan Plc

Amgen Inc

Annexin Pharmaceuticals AB

Arisaph Pharmaceuticals Inc

Athera Biotechnologies AB

Bristol-Myers Squibb Company

Cardax Inc

Cerenis Therapeutics Holding SA

ChemoCentryx Inc

CohBar Inc

Daiichi Sankyo Company Ltd

DoNatur GmbH

Dybly AG

Esperion Therapeutics Inc

Forty Seven Inc

GenKyoTex SA

Immusoft Corp

Iproteos SL

Jenrin Discovery Inc

Kang Stem Biotech Co Ltd

KineMed Inc

Kowa Company Ltd

Lead Discovery Center GmbH

LipimetiX Development Inc

MedImmune LLC

Merck & Co Inc

Omeros Corp

Otsuka Holdings Co Ltd

Resverlogix Corp

Tolerys SA

Unity Biotechnology Inc

Vascular Biogenics Ltd

Vericel Corp

Vicore Pharma AB

XBiotech Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Atherosclerosis - Overview 6

Atherosclerosis - Therapeutics Development 7

Atherosclerosis - Therapeutics Assessment 21

Atherosclerosis - Companies Involved in Therapeutics Development 33

Atherosclerosis - Drug Profiles 51

Atherosclerosis - Dormant Projects 192

Atherosclerosis - Discontinued Products 199

Atherosclerosis - Product Development Milestones 201

Appendix 215

List of Tables

List of Tables

Number of Products under Development for Atherosclerosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Atherosclerosis – Pipeline by AFFiRiS AG, H1 2017

Atherosclerosis – Pipeline by Allergan Plc, H1 2017

Atherosclerosis – Pipeline by Amgen Inc, H1 2017

Atherosclerosis – Pipeline by Annexin Pharmaceuticals AB, H1 2017

Atherosclerosis – Pipeline by Arisaph Pharmaceuticals Inc, H1 2017

Atherosclerosis – Pipeline by Athera Biotechnologies AB, H1 2017

Atherosclerosis – Pipeline by Bristol-Myers Squibb Company, H1 2017

Atherosclerosis – Pipeline by Cardax Inc, H1 2017

Atherosclerosis – Pipeline by Cerenis Therapeutics Holding SA, H1 2017

Atherosclerosis – Pipeline by ChemoCentryx Inc, H1 2017

Atherosclerosis – Pipeline by CohBar Inc, H1 2017

Atherosclerosis – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Atherosclerosis – Pipeline by DoNatur GmbH, H1 2017

Atherosclerosis – Pipeline by Dybly AG, H1 2017

Atherosclerosis – Pipeline by Esperion Therapeutics Inc, H1 2017

Atherosclerosis – Pipeline by Forty Seven Inc, H1 2017

Atherosclerosis – Pipeline by GenKyoTex SA, H1 2017

Atherosclerosis – Pipeline by Immusoft Corp, H1 2017

Atherosclerosis – Pipeline by Iproteos SL, H1 2017

Atherosclerosis – Pipeline by Jenrin Discovery Inc, H1 2017

Atherosclerosis – Pipeline by Kang Stem Biotech Co Ltd, H1 2017

Atherosclerosis – Pipeline by KineMed Inc, H1 2017

Atherosclerosis – Pipeline by Kowa Company Ltd, H1 2017

Atherosclerosis – Pipeline by Lead Discovery Center GmbH, H1 2017

Atherosclerosis – Pipeline by LipimetiX Development Inc, H1 2017

Atherosclerosis – Pipeline by MedImmune LLC, H1 2017

Atherosclerosis – Pipeline by Merck & Co Inc, H1 2017

Atherosclerosis – Pipeline by Omeros Corp, H1 2017

Atherosclerosis – Pipeline by Otsuka Holdings Co Ltd, H1 2017

Atherosclerosis – Pipeline by Resverlogix Corp, H1 2017

Atherosclerosis – Pipeline by Tolerys SA, H1 2017

Atherosclerosis – Pipeline by Unity Biotechnology Inc, H1 2017

Atherosclerosis – Pipeline by Vascular Biogenics Ltd, H1 2017

Atherosclerosis – Pipeline by Vericel Corp, H1 2017

Atherosclerosis – Pipeline by Vicore Pharma AB, H1 2017

Atherosclerosis – Pipeline by XBiotech Inc, H1 2017

Atherosclerosis – Dormant Projects, H1 2017

Atherosclerosis – Dormant Projects, H1 2017 (Contd..1), H1 2017

Atherosclerosis – Dormant Projects, H1 2017 (Contd..2), H1 2017

Atherosclerosis – Dormant Projects, H1 2017 (Contd..3), H1 2017

Atherosclerosis – Dormant Projects, H1 2017 (Contd..4), H1 2017

Atherosclerosis – Dormant Projects, H1 2017 (Contd..5), H1 2017

Atherosclerosis – Dormant Projects, H1 2017 (Contd..6), H1 2017

Atherosclerosis – Discontinued Products, H1 2017

Atherosclerosis – Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

List of Figures

Number of Products under Development for Atherosclerosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports